Canaccord analyst Sumant Kulkarni raised the firm's price target on AtaiBeckley to $15 from $14 and kept a ‘Buy’ rating on ...

Psychedelic-related stocks rose in premarket trading after President Donald Trump signed an executive order aimed at accelerating research and expanding access to substances used abroad to treat ...

ATAI Life Sciences, a biopharmaceutical company aiming to make psychedelic drugs to treat mental health disorders, announced that it is planning to raise $100 million in an initial public offering.

AtaiBeckley Inc. (NASDAQ:ATAI) is one of the best multibagger penny stocks to invest in. On March 27, Deutsche Bank initiated coverage of AtaiBeckley Inc. (NASDAQ:ATAI) with a Buy rating and a $12 ...

A new FDA regulatory pathway could accelerate approval of psychedelic therapies for resistant depression and PTSD, and ...

After President Donald Trump signed an executive order (1) aimed at fast-tracking research and access to psychedelic ...

Wall Street is currently pivoting toward high-growth biotech plays as federal support accelerates a revolution in alternative ...

AtaiBeckley Inc (NASDAQ:ATAI) is among the best psychedelic stocks to buy in 2026. On March 17, AtaiBeckley Inc (NASDAQ:ATAI) announced the publication in the Journal of Psychopharmacology of the ...

NEW YORK and AMSTERDAM, Oct. 20, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (ATAI) (“atai”), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health ...

Atai Life Sciences works on the development of psychedelic and other drugs to treat mental illness. The firm, which counts Peter Thiel as an investor, is looking at going public later this year, ...